Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Hunt for hidden cancer genes: families needed to unlock hereditary secrets

NCT ID NCT03050268

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a registry and sample bank to help future diagnosis and care. Participants may not receive individual results, but the knowledge gained could improve understanding of hereditary cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2017

Expected to finish

Mar 2037

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with cancer and their family members who meet the eligibility criteria shown below.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown below, you may enroll regardless of the results of your clinical genetic testing. DEFINITION OF FAMILIAR CANCER FOR THIS PROTOCOL: In this protocol, the definition of "Familial Cancer" is met if any of the following is present: * An individual with a history of cancer diagnosed under 26 years of age who has at least one first, second or third degree relative with a history of cancer diagnosed under 51 years of age; OR * An individual who has been diagnosed with more than one cancer, at least one of which was diagnosed under 26 years of age; OR * An individual with a clinical or molecular diagnosis of a known cancer predisposition syndrome; OR * An individual with a congenital cancer diagnosed before 6 months of age; OR * An individual with a rare pediatric cancer or tumor diagnosed before 26 years of age º Excluding human papilloma virus-associated cervical cancer and non-melanoma skin cancer occurring in adults. INCLUSION CRITERIA: * An individual who meets this protocol's definition of "Familial Cancer," as above. * Biologic relatives of an individual meeting this protocol's definition of "Familial Cancer," who are either affected or unaffected by cancer. EXCLUSION CRITERIA: * An inability or unwillingness of the research participant or his/her legally authorized representative (LAR) to provide written informed consent. * The participant has received allogeneic bone marrow transplantation and has NO pre-transplant germline (cancer-unaffected) DNA available AND is unwilling to provide a skin sample.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute leukemia acute myeloid leukemia Adenomatous Polyposis Coli adrenal carcinoma adrenal cortex carcinoma atypical teratoid rhabdoid tumor BAP1-related tumor predisposition syndrome Carney complex choroid plexus carcinoma classic familial adenomatous polyposis Colorectal Neoplasms, Hereditary Nonpolyposis Cowden disease deafness-lymphedema-leukemia syndrome Diamond-Blackfan anemia DICER1-related tumor predisposition dyskeratosis congenita familial atypical multiple mole melanoma syndrome Fanconi anemia gastrointestinal stromal tumor GATA2 Deficiency hereditary breast ovarian cancer syndrome hereditary neoplastic syndrome hereditary pheochromocytoma-paraganglioma hereditary Wilms tumor Hodgkins lymphoma inherited acute myeloid leukemia inherited disease susceptibility juvenile polyposis syndrome Li-Fraumeni syndrome Lynch syndrome malignant pancreatic neoplasm melanoma mismatch repair cancer syndrome mismatch repair cancer syndrome 1 multiple endocrine neoplasia type 1 multiple endocrine neoplasia type 2 multiple endocrine neoplasia type 2A myelodysplastic syndrome neuroblastoma Neurofibromatosis 2 neurofibromatosis type 1 nevoid basal cell carcinoma syndrome NF2-related schwannomatosis non-Hodgkin lymphoma Noonan syndrome overgrowth syndrome pancreatic neoplasm paraganglioma Peutz-Jeghers syndrome pheochromocytoma pheochromocytoma-paraganglioma PTEN hamartoma tumor syndrome RASopathy retinoblastoma rhabdomyosarcoma Rothmund-Thomson syndrome tuberous sclerosis von Hippel-Lindau disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • St. Jude Children's Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.